Author: Camurus AB

HCM & HRIS

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

January 11, 2026
Camurus AB
No Comments

PDUFA target action date set to 10 June 2026 , /PRNewswire/ — Camurus (NASDAQ STO: CAMX)…